# Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers

> **NCT03163121** · PHASE1 · COMPLETED · sponsor: **Sanaria Inc.** · enrollment: 67 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** PfSPZ-GA1 Vaccine
- **BIOLOGICAL:** PfSPZ Vaccine
- **OTHER:** Normal Saline
- **BIOLOGICAL:** Mosquito-bite CHMI

## Key facts

- **NCT ID:** NCT03163121
- **Lead sponsor:** Sanaria Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-12
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-25
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03163121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03163121, "Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03163121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*